4
Changes in Ownership
Kiniksa Pharmaceuticals International, plc Filed Acc 0001415889-24-028844
CHIEF FINANCIAL OFFICER sold 27,829 shares at an average $21.34 ($593,997)
- CHIEF FINANCIAL OFFICER acquired 21,266 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Ragosa Mark CHIEF FINANCIAL OFFICER | 2024-12-06 | Option exercise 10b5-1 | +2,406 | $10.76 | $25,889 | 25,364 | D |
| Ragosa Mark CHIEF FINANCIAL OFFICER | 2024-12-06 | Sale 10b5-1 | −8,969 | $21.27 | $190,771 | 22,958 | D |
| Ragosa Mark CHIEF FINANCIAL OFFICER | 2024-12-09 | Option exercise 10b5-1 | +18,860 | $11.10 | $209,346 | 41,818 | D |
| Ragosa Mark CHIEF FINANCIAL OFFICER | 2024-12-09 | Sale 10b5-1 | −18,860 | $21.38 | $403,227 | 22,958 | D |
| Derivatives | |||||||
| Ragosa Mark CHIEF FINANCIAL OFFICER | 2024-12-06 | Option exercise · Share Option 10b5-1 | −2,406 | 24,528 | D | ||
| Ragosa Mark CHIEF FINANCIAL OFFICER | 2024-12-09 | Option exercise · Share Option 10b5-1 | −18,860 | 21,552 | D | ||
| Open-market sales · 27,829 sh · avg $21.34 · $593,997 | |||||||
Loading xslF345X05/form4-12102024_091222.xml…